Skip to main content
. 2018 Oct 1;20(Suppl 4):iv1–iv86. doi: 10.1093/neuonc/noy131

Table 21.

One-, Two-, Five-, and Ten-Year Relative Survival Ratesa,b with 95% Confidence Intervals for Selected Malignant Brain and Other Central Nervous System Tumors by Age Group, SEER 18 Registries, 2000-2015c

Histology Age Group (years) N d 1-Year 2-Year 5-Year 10-Year
% 95% CI % 95% CI % 95% CI % 95% CI
Pilocytic astrocytoma 0-19 3,039 98.7 98.2-99.1 98.2 97.6-98.6 96.6 95.8-97.2 95.7 94.7-96.5
20-44 826 96.7 95.2-97.8 94.5 92.6-95.9 91.5 89.1-93.4 86.1 82.7-88.9
45-54 154 94.4 89.0-97.2 86.1 79.1-90.9 78.8 70.3-85.1 76.0 65.8-83.5
55-64 95 95.2 87.2-98.3 89.9 80.4-95.0 83.0 72.1-89.9 78.7 64.5-87.7
65-74 -- -- -- -- -- -- -- -- --
75+ -- -- -- -- -- -- -- -- --
Diffuse astrocytoma 0-19 977 93.1 91.2-94.5 87.6 85.3-89.6 83.5 80.8-85.8 81.2 78.2-83.8
20-44 2,330 93.5 92.4-94.5 87.4 85.9-88.8 69.2 67.1-71.2 49.6 46.9-52.2
45-54 1,039 77.4 74.7-79.9 63.0 59.8-65.9 44.9 41.5-48.2 32.8 29.1-36.5
55-64 909 58.0 54.6-61.2 38.3 35.0-41.6 23.0 20.0-26.2 14.6 11.5-18.1
65-74 681 43.2 39.4-47.0 26.5 23.0-30.1 15.4 12.4-18.7 11.6 8.3-15.6
75+ 557 25.1 21.4-28.9 13.0 10.1-16.2 6.4 4.1-9.5 1.2 0.1-5.1
Anaplastic astrocytoma 0-19 341 68.9 63.6-73.6 39.3 33.8-44.6 27.0 22.0-32.2 19.5 14.6-24.9
20-44 1,535 89.5 87.8-90.9 75.9 73.5-78.1 55.2 52.2-58.0 39.3 35.9-42.6
45-54 789 74.7 71.4-77.7 51.7 47.9-55.3 31.5 27.8-35.3 22.9 19.0-27.0
55-64 810 55.4 51.7-58.8 30.8 27.4-34.2 13.3 10.6-16.2 6.1 3.8-9.2
65-74 628 37.1 33.2-41.0 18.0 14.9-21.4 7.9 5.6-10.8 5.0 3.0-7.9
75+ 433 18.0 14.4-22.0 8.8 6.1-12.1 1.1 0.3-3.2 0.6 0.1-2.8
Glioblastoma 0-19 516 59.1 54.7-63.3 33.4 29.2-37.7 16.6 13.2-20.4 12.1 8.8-15.9
20-44 3,253 70.4 68.8-72.0 41.6 39.8-43.3 19.1 17.6-20.7 10.9 9.6-12.4
45-54 6,360 57.9 56.7-59.2 25.9 24.7-27.0 7.7 7.0-8.5 3.8 3.2-4.6
55-64 10,027 46.6 45.6-47.6 18.3 17.5-19.1 4.7 4.2-5.2 1.8 1.4-2.3
65-74 9,093 30.0 29.0-31.0 11.1 10.4-11.8 2.6 2.2-3.0 1.0 0.7-1.5
75+ 7,367 12.7 12.0-13.6 3.8 3.3-4.4 1.0 0.7-1.3 0.3 0.1-0.8
Oligodendroglioma 0-19 240 96.6 93.3-98.3 94.8 90.9-97.0 90.9 86.0-94.1 88.6 83.1-92.3
20-44 1,720 98.7 98.0-99.2 96.5 95.5-97.4 88.3 86.4-89.9 71.8 68.9-74.5
45-54 778 94.8 92.8-96.2 90.3 87.8-92.3 81.0 77.6-83.9 64.5 59.7-68.9
55-64 427 89.3 85.8-92.0 80.0 75.5-83.7 69.7 64.2-74.5 53.3 45.9-60.2
65-74 181 81.2 74.2-86.5 73.0 64.9-79.4 54.4 45.0-62.8 38.1 27.0-49.1
75+ 96 63.0 51.3-72.5 51.0 38.9-61.9 39.1 25.9-52.1 -- --
Anaplastic oligodendroglioma 0-19 -- -- -- -- -- -- -- -- --
20-44 575 94.6 92.3-96.2 85.5 82.1-88.3 72.1 67.8-75.9 56.3 51.0-61.4
45-54 385 89.7 86.0-92.4 78.8 74.0-82.8 63.7 57.8-68.9 46.9 40.0-53.5
55-64 311 78.3 73.0-82.6 63.4 57.3-68.8 46.1 39.6-52.3 33.5 26.3-40.8
65-74 139 57.1 48.1-65.1 38.4 29.7-47.0 22.1 14.3-31.0 16.1 8.4-26.1
75+ 57 40.5 26.8-53.7 -- -- -- -- -- --
Ependymal tumors 0-19 880 95.3 93.6-96.5 88.5 86.1-90.6 77.0 73.6-79.9 68.4 64.4-72.0
20-44 987 97.4 96.1-98.2 95.5 93.9-96.7 91.8 89.6-93.6 88.3 85.3-90.7
45-54 570 95.8 93.6-97.2 93.2 90.5-95.1 89.5 86.1-92.1 87.3 83.0-90.6
55-64 413 92.2 89.0-94.6 89.2 85.3-92.1 86.7 81.9-90.2 84.6 77.7-89.5
65-74 208 88.5 82.6-92.5 82.7 75.7-87.8 81.2 73.6-86.8 67.3 52.9-78.2
75+ 97 68.1 56.7-77.1 63.4 51.0-73.5 51.2 36.4-64.3 30.7 13.7-49.6
Oligoastrocytic tumors 0-19 126 93.6 87.5-96.8 88.5 81.2-93.1 81.2 72.6-87.3 76.5 67.0-83.6
20-44 1,194 96.9 95.6-97.7 91.0 89.1-92.6 73.8 70.8-76.5 55.3 51.4-58.9
45-54 450 89.8 86.5-92.3 79.4 75.1-83.0 66.6 61.5-71.2 48.2 41.5-54.5
55-64 259 74.0 68.0-79.0 51.6 45.0-57.8 34.2 27.7-40.8 26.4 19.3-34.0
65-74 145 66.3 57.7-73.6 48.4 39.5-56.7 26.6 18.5-35.4 13.3 6.2-23.2
75+ -- -- -- -- -- -- -- -- --
Glioma malignant, NOS 0-19 1,969 78.6 76.6-80.4 68.0 65.8-70.1 65.1 62.8-67.3 63.4 61.0-65.7
20-44 1,058 88.2 86.0-90.0 80.0 77.3-82.4 69.1 65.9-72.2 56.6 52.4-60.6
45-54 509 75.0 70.9-78.6 60.3 55.7-64.6 49.7 44.9-54.4 39.5 34.0-44.9
55-64 452 58.9 54.1-63.5 45.3 40.3-50.2 35.7 30.6-40.9 29.4 23.5-35.4
65-74 430 39.9 35.2-44.7 26.5 22.1-31.1 17.7 13.6-22.3 15.6 11.1-20.8
75+ 787 18.9 16.1-21.9 14.1 11.5-17.0 9.7 7.0-12.7 8.5 5.5-12.4
Neuronal and mixed neuronal-glial tumors 0-19 73 94.4 85.8-97.9 88.5 78.2-94.1 83.6 72.1-90.6 83.6 72.1-90.6
20-44 161 95.6 90.7-97.9 90.1 83.9-94.0 78.5 70.3-84.7 63.9 53.1-72.8
45-54 143 93.8 88.0-96.9 90.3 83.5-94.4 85.1 77.0-90.5 77.3 64.8-85.8
55-64 124 91.4 84.3-95.4 82.5 73.5-88.7 69.7 58.5-78.5 51.3 36.4-64.4
65-74 68 86.2 74.2-92.9 84.5 71.2-92.0 76.1 58.3-87.1 55.1 28.1-75.6
75+ -- -- -- -- -- -- -- -- --
Embryonal tumors 0-19 2,312 81.5 79.8-83.1 71.8 69.9-73.7 62.8 60.6-64.8 56.7 54.3-59.0
20-44 627 87.1 84.1-89.5 80.0 76.5-83.1 66.9 62.6-70.8 58.9 54.1-63.4
45-54 91 82.4 72.7-88.9 69.8 58.9-78.4 54.0 42.2-64.5 38.4 25.7-50.9
55-64 52 68.2 53.1-79.3 48.7 33.8-62.1 -- -- -- --
65-74 -- -- -- -- -- -- -- -- --
75+ -- -- -- -- -- -- -- -- --
Meningioma 0-19 -- -- -- 81.4 52.4-93.7 81.4 52.4-93.7 81.4 52.4-93.7
20-44 149 94.7 89.4-97.4 94.1 88.6-97.0 87.7 80.5-92.3 78.7 69.7-85.3
45-54 195 93.1 88.2-96.0 85.8 79.7-90.2 77.9 70.6-83.6 70.8 62.2-77.8
55-64 291 88.2 83.6-91.5 81.1 75.7-85.4 68.7 62.1-74.4 59.9 52.2-66.7
65-74 270 80.6 75.0-85.1 69.5 63.0-75.2 51.4 43.8-58.5 46.1 36.6-55.1
75+ 307 63.4 57.1-69.0 55.6 48.7-61.9 46.4 38.1-54.2 34.3 24.1-44.7
Lymphoma 0-19 70 84.0 72.9-90.8 76.5 64.4-84.9 71.7 59.2-81.0 67.3 53.9-77.7
20-44 834 57.7 54.2-61.0 52.0 48.4-55.4 45.9 42.2-49.5 40.7 36.8-44.6
45-54 784 63.0 59.5-66.4 54.2 50.5-57.7 42.7 38.8-46.5 32.2 28.1-36.4
55-64 1,121 62.5 59.5-65.3 53.6 50.5-56.6 39.8 36.5-43.1 29.3 25.6-33.1
65-74 1,311 51.5 48.7-54.3 42.6 39.7-45.5 29.0 26.0-32.1 18.9 15.5-22.7
75+ 1,083 34.0 31.0-37.0 24.6 21.8-27.5 16.1 13.2-19.2 11.6 7.9-16.1
TOTAL 0-19 11,985 87.4 86.8-88.0 80.0 79.3-80.8 74.1 73.2-74.9 70.7 69.7-71.6
20-44 16,324 86.8 86.3-87.4 76.3 75.6-77.0 62.2 61.4-63.1 50.1 49.1-51.1
45-54 12,738 69.8 68.9-70.6 48.5 47.6-49.4 33.5 32.6-34.4 26.2 25.2-27.2
55-64 15,805 54.4 53.6-55.2 31.6 30.8-32.4 18.5 17.8-19.2 13.7 13.0-14.4
65-74 13,797 37.3 36.4-38.1 20.9 20.2-21.6 11.5 10.9-12.2 8.2 7.5-8.9
75+ 12,511 18.3 17.6-19.1 10.4 9.8-11.0 6.1 5.6-6.7 4.0 3.4-4.7

aThe cohort analysis of survival rates was utilized for calculating the survival estimates presented in this table. Long-term cohort-based survival estimates reflect the survival experience of individuals diagnosed over the time period, and they may not necessarily reflect the long-term survival outlook of newly diagnosed cases.

bRates are an estimate of the percentage of patients alive at one, two, five, and ten years, respectively. Rates were not presented for categories with 50 or fewer cases and were suppressed for rates where fewer than 16 cases were surviving within a category.

cEstimated by CBTRUS using Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Incidence - SEER 18 Regs Research Data + Hurricane Katrina Impacted Louisiana Cases, Nov 2017 Sub (2000-2015) <Katrina/Rita Population Adjustment> - Linked To County Attributes - Total U.S., 1969-2016 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, Surveillance Systems Branch, released April 2018, based on the November 2017 submission.

dTotal number of case that occurred within the SEER registries between 2000 and 2015.

eTotal includes histologies not listed in this table.

-- Counts and rates are not presented for categories with 50 or fewer cases and were suppressed for rates where fewer than 16 cases were surviving within a category. The suppressed cases are included in the counts and rates for totals.

Abbreviation: CBTRUS, Central Brain Tumor Registry of the United States; SEER, Survival, Epidemiology, and End Results; CI, confidence interval; NOS, not otherwise specified